Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial

Hongzhou Lu; George Zhang; John Mao; Xiaochun Chen; Yangqing Zhan; Ling Lin; Tianxiang Zhang; Yanan Tang; Feng Lin; Feiyue Zhu; Yuanlong Lin; Yiming Zeng; Kaiyu Zhang; Wenfang Yuan; Zhenyu Liang; Ruilin Sun; L. Huo; Peng Hu; Yihua Lin; Xibin Zhuang; Zhaohui Wei; Xia Chen; Wenhao Yan; Xiu‐Ping Yan; L.M. Mu; Zhuhua Lin; Xinyu Tu; Hongshan Tan; Fuhu Huang; Zhiqiang Hu; Hongming Li; Guoping Li; Haijun Fu; Zifeng Yang; Xinwen Chen; Fu‐Sheng Wang; Nanshan Zhong

doi:10.1016/j.eclinm.2024.102582

Abstract

GST-HG171 is a potent, broad-spectrum, orally bioavailable small-molecule 3C like protease inhibitor that has demonstrated greater potency and efficacy compared to Nirmatrelvir in pre-clinical studies. We aimed to evaluate the efficacy and safety of orally administered GST-HG171 plus Ritonavir in patients with coronavirus disease 2019 (COVID-19) infected with emerging XBB and non-XBB variants.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lu et al. (2024) studied this question.

synapsesocial.com/papers/68e6f97db6db6435876742bd https://doi.org/10.1016/j.eclinm.2024.102582

View Full Paper

Ask AI

Bookmark

Share

Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial

Abstract

Discussion

Cite This Study

Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading